Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Prostate Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 100 active trials
7 drugs · 60 active trials
24 drugs · 405 active trials
Outside the funnel: Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Enzalutamide | Approved | Phase 4 | 66 | 35 | 28 | 183 | 15 | EU, US | Aug 31, 2012 | Jul 8, 2005 |
| Docetaxel | Approved | Phase 3 | 41 | 22 | 47 | 222 | 8 | US | May 14, 1996 | 1997-08 |
| Abiraterone Acetate | Approved | Phase 4 | 38 | 13 | 14 | 104 | 4 | EU, US | May 22, 2018 | 2007-06 |
| Darolutamide | Approved | Phase 4 | 36 | 20 | 11 | 51 | 2 | EU, US | Jul 30, 2019 | 2011-03 |
| Apalutamide | Approved | Phase 3 | 31 | 13 | 14 | 64 | 2 | EU, US | Feb 14, 2018 | Feb 5, 2013 |
| Leuprolide | Approved | Phase 4 | 30 | 14 | 33 | 120 | 9 | EU, US | Jan 26, 1989 | 1994-10 |
| Abiraterone | Approved | Phase 4 | 30 | 18 | 13 | 74 | 3 | EU, US | Sep 5, 2011 | Jul 8, 2005 |
| Degarelix | Approved | Phase 4 | 20 | 7 | 30 | 80 | 3 | EU, US | Dec 24, 2008 | 2001-03 |
| Bicalutamide | Approved | Phase 4 | 17 | 6 | 36 | 104 | 1 | US | Oct 4, 1995 | 1994-12 |
| Goserelin | Approved | Phase 4 | 17 | 7 | 37 | 93 | 4 | US | Dec 29, 1989 | 1987-05 |
| Olaparib | Approved | Phase 4 | 16 | 2 | 4 | 39 | 2 | US | Aug 17, 2017 | 2012-07 |
| Relugolix | Approved | Phase 3 | 16 | 10 | 6 | 23 | 2 | EU, US | Dec 18, 2020 | 2014-03 |
| Cabazitaxel | Approved | Phase 4 | 15 | 6 | 10 | 45 | 3 | EU, US | Jun 17, 2010 | 2011-01 |
| Triptorelin | Approved | Phase 4 | 9 | 6 | 13 | 31 | 3 | US | Jun 15, 2000 | 1997-04 |
| Flutamide | Approved | Phase 4 | 5 | 1 | 24 | 42 | 1 | US | Sep 18, 2001 | 1994-10 |
| Talazoparib | Approved | Phase 2 | 5 | 3 | 0 | 13 | 2 | US | Oct 16, 2018 | Jan 3, 2011 |
| Niraparib | Approved | Phase 2 | 4 | 2 | 0 | 9 | 1 | EU | Apr 19, 2023 | 2016-03 |
| Nilutamide | Approved | Phase 3 | 3 | 1 | 5 | 10 | 1 | US | Jul 15, 2016 | Feb 8, 1995 |
| Capivasertib | Approved | Phase 3 | 3 | 1 | 1 | 7 | 1 | US | Nov 16, 2023 | Jan 29, 2014 |
| Rucaparib | Approved | Phase 3 | 2 | 0 | 3 | 11 | 1 | US | Dec 19, 2016 | Feb 15, 2017 |
| Denosumab | Approved | Phase 4 | 1 | 0 | 4 | 7 | 6 | US | Jun 1, 2010 | Aug 1, 2004 |
| Padeliporfin | Approved | Phase 3 | 0 | 0 | 1 | 3 | 1 | EU | Nov 10, 2017 | 2008-09 |
| Radium Ra-223 Dichloride | Approved | Phase 2 | 0 | 0 | 0 | 1 | 1 | US | May 15, 2013 | Jun 25, 2014 |
| Radium Ra223 dichloride | Approved | — | 0 | 0 | 0 | 0 | 1 | EU | Nov 13, 2013 | — |
| Prednisone | Phase 4 | Phase 4 | 44 | 21 | 37 | 188 | 0 | — | — | Nov 24, 1997 |
| Dexamethasone | Phase 4 | Phase 4 | 5 | 3 | 6 | 27 | 0 | — | — | 1999-06 |
| Metformin | Phase 4 | Phase 4 | 4 | 1 | 3 | 28 | 0 | — | — | Jul 8, 2005 |
| Prednisolone | Phase 4 | Phase 4 | 4 | 2 | 2 | 15 | 0 | — | — | 2005-02 |
| Aspirin | Phase 4 | Phase 4 | 2 | 1 | 4 | 7 | 0 | — | — | Nov 14, 2002 |
| Zoledronic Acid | Phase 4 | Phase 4 | 1 | 0 | 12 | 35 | 0 | — | — | 1999-09 |
| Pasireotide | Phase 4 | Phase 4 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-06 |
| Lutetium (177lu) Vipivotide Tetraxetan | Phase 3 | Phase 3 | 20 | 14 | 2 | 29 | 0 | — | — | 2016-12 |
| Carboplatin | Phase 3 | Phase 3 | 17 | 8 | 3 | 43 | 0 | — | — | 1998-04 |
| Nivolumab | Phase 3 | Phase 3 | 14 | 3 | 2 | 35 | 0 | — | — | 2006-08 |
| Atezolizumab | Phase 3 | Phase 3 | 9 | 4 | 2 | 12 | 0 | — | — | Sep 5, 2017 |
| Cabozantinib | Phase 3 | Phase 3 | 8 | 3 | 4 | 21 | 0 | — | — | 2011-04 |
| Ipilimumab | Phase 3 | Phase 3 | 6 | 2 | 2 | 28 | 0 | — | — | May 13, 2003 |
| Hormone Therapy | Phase 3 | Phase 3 | 4 | 1 | 5 | 9 | 0 | — | — | 2003-06 |
| Histrelin | Phase 3 | Phase 3 | 4 | 2 | 4 | 6 | 0 | — | — | 2000-04 |
| Etoposide | Phase 3 | Phase 3 | 3 | 1 | 1 | 12 | 0 | — | — | 1997-12 |
| Cisplatin | Phase 3 | Phase 3 | 3 | 2 | 1 | 9 | 0 | — | — | 1998-09 |
| Paclitaxel | Phase 3 | Phase 3 | 2 | 1 | 2 | 28 | 0 | — | — | 1997-04 |
| Bevacizumab | Phase 3 | Phase 3 | 2 | 2 | 2 | 18 | 0 | — | — | 2001-06 |
| Abemaciclib | Phase 3 | Phase 3 | 2 | 1 | 1 | 8 | 0 | — | — | Nov 26, 2018 |
| Buserelin | Phase 3 | Phase 3 | 2 | 0 | 5 | 6 | 0 | — | — | Feb 8, 1995 |
| Ipatasertib | Phase 3 | Phase 3 | 2 | 0 | 1 | 5 | 0 | — | — | Jan 11, 2012 |
| Celecoxib | Phase 3 | Phase 3 | 1 | 0 | 2 | 10 | 0 | — | — | 2001-05 |
| Tamoxifen | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | 2002-11 |
| Estramustine | Phase 3 | Phase 3 | 0 | 0 | 7 | 40 | 0 | — | — | 1995-03 |
| Mitoxantrone | Phase 3 | Phase 3 | 0 | 0 | 6 | 24 | 0 | — | — | 1997-03 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.